Nuevolution start trading of its shares on Nasdaq Stockholm main market

Stockholm, 25 June 2018 @ 09:00:00. “Tio nio åtta … tre två ett”, in this very moment, and with the sound of the bell, Nuevolution AB (publ) opened the financial markets in Stockholm and started trading of its shares (ticker: NUE) on Nasdaq Stockholm main market.

Nuevolution was listed on Nasdaq Stockholm First North Premier on the 17th of December 2015.

We identified the Premier segment of Nasdaq’s First North market as the optimal trading platform for the company. The IPO of Nuevolution in 2015 was a very important milestone for the company. It catalyzed the development of our drug candidate pipeline significantly, and under strict conditions and in a good and competitive environment, the First North Premier market place has trained us optimally in preparation of this day. In September 2017, we announced the intention to apply for the listing on the main market before end of first half of 2018, and today, we may pleasingly conclude, that it is the first day of trading on the main market for Nuevolution.

This represents another major goal for the company. The listing on the main market only follows after a significant scrutiny of the company’s operations, evaluation of the company’s fitness and assessment of skills and experience of board and management. Being allowed for trading on the main market is an honor, and it represents a quality stamp, that will support our ambitious intentions for further growth and value creation, and as a main market company, now with a reach towards larger institutional and internal investors also.

This is not an achievement by management alone. This is the result of a team effort of staff, management, board, advisors, but not the least and most importantly our many supportive shareholders and active investors without whom all of this would not have been possible!

On behalf of the board, management and staff of Nuevolution, we wish to express our sincere appreciation for the support that we receive on a daily basis from a strong and loyal investor base. The main market listing offers us even better conditions for long-term growth and value creation to the benefit of shareholders and the equally import aim, to discover better and safer treatment of cancer and severe inflammatory diseases. We are looking forward to continuing this joint team effort.

Stockholm, 25 June 2018

Alex Haahr Gouliaev
Chief Executive Officer

 

This message does not change the conclusion of any messages previously released by Nuevolution AB (publ.) including in connection with its previously released quarterly reports, annual report and press releases.